Contract
Exhibit 10.16
NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST.
June 28, 2018
00000 Xxxxxxxx Xxxxxx
Xxxxxxx, Xxxxxxx 00000
Attn: Chief Financial Officer
Re: Letter Agreement re: Marketing Approval in [****]
To Whom It May Concern:
Reference is made to (i) the Exclusive Distribution Agreement made and entered into between Biomet 3i LLC (‘ZBD’) and RTI Surgical, Inc. (‘RTI’) as of September 30, 2010 (as amended, the ‘Distribution Agreement’), and (ii) the letter agreement dated January 31, 2017, between ZBD to RTI concerning, among other things, Marketing Approvals in [****] (the ‘2017 Letter Agreement’). Defined terms that are used but not defined in this letter agreement shall have the meanings given to them in the 2017 Letter Agreement.
The Parties hereby agree that paragraph 1 in the 2017 Letter Agreement (with the heading ‘Marketing Approval in [****]) is null and void, and that the Parties are hereby released from any obligations set forth in such paragraph including, without limitation, RTI’s obligations to seek Marketing Approvals for the Subject Implants in [****], and ZBD’s obligation to reimburse RTI for certain costs and expenses in connection therewith. The Parties may, but shall not be required to, reevaluate at a later date opportunities for seeking Marketing Approvals for the Subject Implants in [****].
Except as specifically set forth above, the 2017 Letter Agreement and the Distribution Agreement shall remain in full force and effect and are hereby ratified and confirmed. This letter agreement shall be governed by and construed in accordance with the laws of the State of Illinois, without regard to its choice of law rules.
[Remainder of page intentionally left blank;
Signatures appear on following page]
NOTE: PORTIONS OF THIS EXHIBIT INDICATED BY [****] ARE SUBJECT TO A CONFIDENTIAL TREATMENT REQUEST AND HAVE BEEN OMITTED FROM THIS EXHIBIT. COMPLETE, UNREDACTED COPIES OF THIS EXHIBIT HAVE BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AS A PART OF THIS COMPANY’S CONFIDENTIAL TREATMENT REQUEST.
If the provisions above are acceptable to RTI, please execute this letter agreement in the space below and return a signed copy to ZBD.
| Sincerely, | ||
| Biomet 3i LLC | ||
| By: | /s/ X.X. Xxxxxxxxxxx | |
| Name: | X.X. Xxxxxxxxxxx | |
| Title: | Marketing Director | |
| Date: | June 29, 2018 | |
| Acknowledged and agreed: | ||
| By: | /s/ Olivier M. Visa | |
| Name: | Olivier M. Visa | |
| Title: | Vice President OEM, Sports and Donor Services | |
| Date: | July 9, 2018 | |
| cc: | Corporate Counsel | |
| RTI Surgical, Inc. | ||
| 00000 Xxxxxxxx Xxxxxx | ||
| Xxxxxxx, XX 00000 |
